ÜBAG MVZ Dr. Vehling-Kaiser GmbH Dingolfing
- Address
- lock Available on a paid plan
ÜBAG MVZ Dr. Vehling-Kaiser GmbH Dingolfing - Lymphoma Research Center
ÜBAG MVZ Dr. Vehling-Kaiser GmbH Dingolfing is a medical research center specializing in hematologic malignancies with a particular focus on lymphoma treatment protocols. The center participates in multicenter clinical trials investigating novel therapeutic approaches for patients with various lymphoma subtypes, emphasizing both efficacy and patient quality of life outcomes.
- Marginal Zone Lymphoma (MZL) treatment strategies combining targeted therapy and immunotherapy
- Evaluation of combination regimens with Copanlisib and Rituximab in relapsed or treatment-ineligible patients
- Long-term toxicity monitoring and secondary malignancy surveillance in lymphoma patients
The center demonstrates expertise in conducting phase II oncology trials that assess both therapeutic response rates and comprehensive safety profiles. Their research approach includes careful evaluation of complete remission rates using established criteria such as GELA for gastric MALT lymphoma and Cheson 2007 criteria for various MZL subtypes. The center places significant emphasis on patient-centered outcomes, including quality of life assessments and documentation of treatment-associated adverse events, contributing valuable data to the understanding of optimal therapeutic strategies for marginal zone lymphoma patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ÜBAG MVZ Dr. Vehling-Kaiser GmbH Dingolfing
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Copanlisib and Rituximab in Marginal Zone Lymphoma Patients - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (COUP-1) | Universitaetsklinikum Ulm AöR | Phase II | Not Recruiting | Nov 2019 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 1 | Unknown | 2021-10-21 | 2021-10-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.